Compugen Ltd.
Compugen Announces Discovery of Biomarker Candidate for Diagnosis of Ovarian Cancer and Signing of Collaboration Agreement
Published in Medical Patent Week, February 22nd, 2009
Compugen Ltd. (NASDAQ:CGEN) disclosed today the discovery and experimental verification of CGEN-327, a novel molecular biomarker candidate for the diagnosis of ovarian cancer. CGEN-327 is a previously unknown splice variant of the HE4 (Human Epididymis Protein 4) gene, which is a known biomarker for ovarian cancer. The company also announced that it has entered into a research and license option agreement for the product candidate with a leading diagnostic company. Patent coverage for this discovery is being pursued by Compugen.
Anat Cohen-Dayag, vice president of R&D for Compugen, stated, “This is an excellent example of Compugen’s unique 'discovery on demand'...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Week
Source: Medical Patent Week (2009-02-22)
More Articles from Medical Patent Week
- Acacia Research Corporation
Acacia Subsidiary Licenses Medical Picture Archiving and Communication System PACS Technology to Viztek - Alliacense
German Court Affirms Validity of MMP Patent - Biomedicine
Researchers at Rutgers University publish new data on biomedicine - Business News
Cresset BioMolecular Discovery Launches FieldStere, a smart, easy to use software that generates non-obvious drug candidates - Chemoembolization
Research from Ohio State University provides new data about chemoembolization - CyDex Pharmaceuticals
CyDex Pharmaceuticals Announces Successful Completion of Phase II Clinical Trial for Budesonide/Azelastine Combination Solution Nasal Spray - More from this issue of Medical Patent Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
